Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia

The management of chronic myeloid leukemia (CML) has been revolutionized by the discovery of tyrosine kinase inhibitors (TKIs) against BCR-ABL1 oncogenic fusion protein. Imatinib, the first BCR-ABL1 TKI, was introduced into clinical practice in the early 2000s. In the following years, the so-called...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiribelli, Mario, Eskazan, Ahmet Emre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360015/
https://www.ncbi.nlm.nih.gov/pubmed/32699984
http://dx.doi.org/10.1007/s40487-019-00098-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360015/
https://www.ncbi.nlm.nih.gov/pubmed/32699984
http://dx.doi.org/10.1007/s40487-019-00098-w

Ejemplares similares